Table 3.

Immune-related adverse events ipilimumab. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.02. No grade 4 adverse events were reported. One death was determined by the investigators to be related to ipilimumab (inflammatory colitis with bowel perforation).

	Any grade	Grade 1	Grade 2	Grade 3	Grade 5
Any immune-related adverse event	28 (58.3%)	17 (35.4%)	4 (8.3%)	9 (18.8%)	1 (2.1%)
Dermatitis	14 (29.2%)	13 (27.1%)	0	1 (2.1%)	0
Diarrhea/colitis	13 (27.1%)	5 (10.4%)	2 (4.2%)	5 (10.4%)	1 (2.1%)
Uveitis	3 (6.3%)	0	1 (2.1%)	2 (4.2%)	0
Conjunctivitis	2 (4.2%)	2 (4.2%)	0	0	0
Hypophysitis	1 (2.1%)	0	0	1 (2.1%)	0
Pneumonitis	1 (2.1%)	0	1 (2.1%)	0	0
Vitiligo	1 (2.1%)	1 (2.1%)	0	0	0
Treatment-related adverse event leading to discontinuation	5 (10.4%)	0	1 (2.1%)	3 (6.3%)	1 (2.1%)